Pyxis Oncology Inc (PYXS)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $188.98M
Last updated: Nov 17, 2026 at 4:26 PM ET
Pyxis Oncology Inc (PYXS) Statistics
Pyxis Oncology (PYXS) has a market cap of $188.98M and an enterprise value of $185.12M. It kept -852.17% of revenue as net income over the last 12 months. Revenue grew 463.09% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 2.04% below the market cap, as cash exceeds debt.
| Market Cap | $188.98M |
|---|---|
| Enterprise Value | $185.12M |
| Latest price (Nov 17, 2026) | $1.44 |
Key Dates
The next earnings report is expected on Mar 22, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 22, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 5, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.8x and 2.9x. Its year-end P/S ranged from 4.9x to 41.8x from 2023 to 2025.
| P/S Ratio | 11.8x |
|---|---|
| P/B Ratio | 2.9x |
Price Statistics
The stock is down 66.97% over 52 weeks and trades 35.43% below its 50-day average.
| Beta (1Y) | 1.21 |
|---|---|
| 52-Week Change | -66.97% |
| 1-Month Change | -18.18% |
| 3-Month Change | -57.27% |
| 6-Month Change | -24.61% |
| 5-Year Change | -86.43% |
| Total Return (1Y) | -66.97% |
| Total Return (3Y CAGR) | +0.23% |
| Total Return (5Y CAGR) | -35.75% |
| Return vs SPY (1Y) | -81.05% |
| Max Drawdown (1Y) | -80.15% |
| Max Drawdown (3Y) | -86.69% |
| Sharpe Ratio (1Y) | -0.90 |
| Correlation with SPY (1Y) | 0.13 |
| 50-Day Average | $2.23 |
| 200-Day Average | $2.16 |
| 52-Week Range | $1.03 to $5.55 |
| RSI (14 Days) | 31.1 |
| Average Volume (20 Days) | 779.54K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 2.96x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 2.96x |
|---|---|
| Quick Ratio | 2.96x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -209.85% over the last 12 months, against a 5-year average of -75.19%.
| Return on Equity (ROE) | -209.85% |
|---|---|
| Return on Assets (ROA) | -112.95% |
| ROE (5Y Average) | -75.19% |
| ROA (5Y Average) | -52.58% |
| Asset Turnover | 0.11x |
Scores
PYXS has an Altman Z-Score of -10.39, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | -10.39 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $10.18M over the last 12 months.
| Revenue | $10.18M |
|---|---|
| Revenue Growth (YoY) | +463.09% |
| Gross Profit | $7.79M |
| Operating Income | -$89.17M |
| Pretax Income | -$85.61M |
| Net Income | -$86.71M |
| Reported EPS (TTM) | -$1.30 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 53.82% of the $76.77M in total assets.
| Cash and Equivalents | $3.86M |
|---|---|
| Total Debt | $0 |
| Net Cash | $3.86M |
| Net Cash Per Share | $0.05 |
| Working Capital | $39.19M |
| Shareholder Equity | $41.32M |
| Book Value Per Share | $0.49 |
| Total Assets | $76.77M |
| Total Liabilities | $35.45M |
Balance sheet as of Sep 30, 2026.
Cash Flow
| Operating Cash Flow | -$70.93M |
|---|---|
| FCF Per Share | -$0.59 |
| Depreciation and Amortization | $5.10M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -876.34%.
| Gross Margin | 76.53% |
|---|---|
| Operating Margin | -876.34% |
| Pretax Margin | -841.33% |
| Net Margin | -852.17% |
Growth
| Book Value Per Share Growth (2Y CAGR) | -44.68% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -38.41% |
Dividends and Yields
PYXS does not pay a dividend.
| Buyback Yield | -40.29% |
|---|---|
| Shareholder Yield | -40.29% |
Peer Position
Against 6 similar companies, PYXS has the 3rd highest P/S.
P/S RatioPeer median 4.1x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median -31.10%
| P/S Ratio | 11.8x vs 4.1x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +463.09% vs -31.10% median |
Analyst Forecast
Consensus estimates put revenue growth at -99.86% a year over the next fiscal year.
| Revenue Growth Forecast (1Y CAGR) | -99.86% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PYXS
What is PYXS's market cap?
Pyxis Oncology has a market cap of $188.98M. Its enterprise value, which adds debt and subtracts cash, is $185.12M.
How many shares of PYXS are outstanding?
Pyxis Oncology has 83.51M shares outstanding. The count is up 33.49% from a year earlier.
Does PYXS pay a dividend?
No. Pyxis Oncology does not pay a dividend.
How much debt does PYXS have?
Pyxis Oncology has $0 of total debt and $3.86M of cash and equivalents, a net cash position of $3.86M.
PYXS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors